Media Summary: Precision Cancer Medicine specialist, Alex Rolland, discusses Shaheenah Dawood discusses abstracts presented at ESMO Congress 2022: - 210O - Mutational signature analysis reveals ... This video is part of the HMP Education content archive and may include previously accredited educational material. While this ...

The Truth About Cdk4 6 - Detailed Analysis & Overview

Precision Cancer Medicine specialist, Alex Rolland, discusses Shaheenah Dawood discusses abstracts presented at ESMO Congress 2022: - 210O - Mutational signature analysis reveals ... This video is part of the HMP Education content archive and may include previously accredited educational material. While this ... In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights ... Panelists Adam M. Brufsky, MD, PhD; Carlos L. Arteaga, MD; José Baselga, MD, PhD; Denise A. Yardley, MD; and Debu Tripathy, ... This content has been developed for healthcare professionals only. Patients who seek health information should consult with their ...

Rena D. Callahan, MD, a breast medical oncologist at UCLA Health and an associate clinical professor of medicine at the David ... Sarah L. Sammons, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving treatment landscape for patients with ... This video discusses the mechanism of action of cancer therapies - cell cycle inhibitors - Drs. Christopher M. Gallagher and Adam Brufsky discuss real-world evidence to expand knowledge of

Photo Gallery

The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast Cancers
CDK4/6 Inhibitors for Breast Cancer: A Guide for Patients
CDK 4/6 Inhibitors for Breast Cancer: How They Work, Who Gets Them, What to Expect
Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer
Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - First-line Therapy
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HE...
CDK4/6 Inhibitors for Breast Cancer Explained
Emerging CDK4/6-Targeted Therapy for Breast Cancer
Key Steps to Success With CDK4/6 Inhibition in Early Through Metastatic Breast Cancer
Dr Callahan on the Use of CDK4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer
Treatment landscape post-CDK4/6 inhibitors in HR+/HER2-low metastatic breast cancer
Cell cycle inhibitors - CDK4/6 inhibitors
View Detailed Profile
The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast Cancers

The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast Cancers

Precision Cancer Medicine specialist, Alex Rolland, discusses

CDK4/6 Inhibitors for Breast Cancer: A Guide for Patients

CDK4/6 Inhibitors for Breast Cancer: A Guide for Patients

What are

CDK 4/6 Inhibitors for Breast Cancer: How They Work, Who Gets Them, What to Expect

CDK 4/6 Inhibitors for Breast Cancer: How They Work, Who Gets Them, What to Expect

What are

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer

Shaheenah Dawood discusses abstracts presented at ESMO Congress 2022: - 210O - Mutational signature analysis reveals ...

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - First-line Therapy

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - First-line Therapy

This video is part of the HMP Education content archive and may include previously accredited educational material. While this ...

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HE...

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HE...

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights ...

CDK4/6 Inhibitors for Breast Cancer Explained

CDK4/6 Inhibitors for Breast Cancer Explained

CDK4

Emerging CDK4/6-Targeted Therapy for Breast Cancer

Emerging CDK4/6-Targeted Therapy for Breast Cancer

Panelists Adam M. Brufsky, MD, PhD; Carlos L. Arteaga, MD; José Baselga, MD, PhD; Denise A. Yardley, MD; and Debu Tripathy, ...

Key Steps to Success With CDK4/6 Inhibition in Early Through Metastatic Breast Cancer

Key Steps to Success With CDK4/6 Inhibition in Early Through Metastatic Breast Cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their ...

Dr Callahan on the Use of CDK4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer

Dr Callahan on the Use of CDK4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer

Rena D. Callahan, MD, a breast medical oncologist at UCLA Health and an associate clinical professor of medicine at the David ...

Treatment landscape post-CDK4/6 inhibitors in HR+/HER2-low metastatic breast cancer

Treatment landscape post-CDK4/6 inhibitors in HR+/HER2-low metastatic breast cancer

Sarah L. Sammons, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving treatment landscape for patients with ...

Cell cycle inhibitors - CDK4/6 inhibitors

Cell cycle inhibitors - CDK4/6 inhibitors

This video discusses the mechanism of action of cancer therapies - cell cycle inhibitors -

Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects

Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects

Drs. Christopher M. Gallagher and Adam Brufsky discuss real-world evidence to expand knowledge of